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Abstract
Background: Complicated skin and skin structure infections (cSSSIs) frequently result in hospitalization with
significant morbidity and mortality.
Methods: In this phase 3b/4 parallel, randomized, open-label, comparative study, 531 subjects with cSSSI received
tigecycline (100 mg initial dose, then 50 mg intravenously every 12 hrs) or ampicillin-sulbactam 1.5-3 g IV every
6 hrs or amoxicillin-clavulanate 1.2 g IV every 6-8 hrs. Vancomycin could be added at the discretion of the
investigator to the comparator arm if methicillin-resistant Staphylococcus aureus (MRSA) was confirmed or suspected
within 72 hrs of enrollment. The primary endpoint was clinical response in the clinically evaluable (CE) population
at the test-of-cure (TOC) visit. Microbiologic response and safety were also assessed. The modified intent-to-treat
(mITT) population comprised 531 subjects (tigecycline, n = 268; comparator, n = 263) and 405 were clinically
evaluable (tigecycline, n = 209; comparator, n = 196).
Results: In the CE population, 162/209 (77.5%) tigecycline-treated subjects and 152/196 (77.6%) comparator-treated
subjects were clinically cured (difference 0.0; 95% confidence interval [CI]: -8.7, 8.6). The eradication rates at the
subject level for the microbiologically evaluable (ME) population were 79.2% in the tigecycline treatment group and
76.8% in the comparator treatment group (difference 2.4; 95% CI: -9.6, 14.4) at the TOC assessment. Nausea,
vomiting, and diarrhea rates were higher in the tigecycline group.
Conclusions: Tigecycline was generally safe and effective in the treatment of cSSSIs.
Trial registration: ClinicalTrials.gov NCT00368537
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Background
Skin and skin structure infections are classified as
complicated (cSSSIs) if the infection has spread to the
deeper tissues, surgical intervention is required, or the
patient has a comorbid condition (e.g. diabetes mellitus)
that complicates response to treatment [1]. Although
most community-acquired skin infections are caused
by Staphylococcus aureus and Streptococcus pyogenes,
cSSSIs may have a diverse bacterial etiology depending
on the clinical diagnosis, anatomic location, and health-
care setting [2-5]. The availability of therapies effective
against a variety of pathogens including community-
acquired methicillin-resistant S. aureus (CA-MRSA) may
be desirable with certain cSSSIs.
Tigecycline is an intravenous expanded broad-spectrum
glycylcycline with in vitro activity against pathogens asso-
ciated with cSSSI [6,7]. The in vitro activity includes
Gram-positive and Gram-negative organisms (except
Pseudomonas spp.), anaerobes, atypical organisms, and
some multidrug-resistant pathogens [8-11]. Tigecycline
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is not affected by classical tetracycline resistance
mechanisms and has no cross-resistance with common
resistance mechanisms in other classes of antibiotics;
however, resistance to tigecycline via non-specific multi-
drug efflux pumps has been demonstrated [12].
Tigecycline has previously been found to be non-
inferior to the combination of vancomycin and aztreonam
in adults for the treatment of cSSSI in two randomized,
double-blind, phase 3 trials [13,14]. Here, the efficacy
and safety of tigecycline in hospitalized patients was
compared with that of ampicillin-sulbactam or amoxicillin-
clavulanate, which are commonly used in the treatment
of cSSSI.
Methods
A phase 3b/4, randomized, open-label, comparative study
was conducted in subjects with cSSSI between September
2006 and September 2008 at 77 centers worldwide. The
protocol (Pfizer Inc, data on file) was approved by the
ethics committee of each participating center and written
informed consent was obtained from each subject prior
to enrollment. The study was block randomized by site
(block size of 4); allocation sequence was not provided
to investigators. Investigators were responsible for sub-
ject enrollment. Subjects were centrally randomized by
computer at a 1:1 ratio to receive either tigecycline or
comparator for a minimum of 4 days and a maximum
of 14 days. Subjects assigned to tigecycline received
100 mg IV followed by 50 mg every 12 hrs. Subjects
assigned to the comparator received ampicillin-sulbactam
1.5 to 3 g IV every 6 hrs or amoxicillin-clavulanate 1.2 g
IV every 6 to 8 hrs. Vancomycin 1 g IV every 12 hrs
could be added to the comparator regimen if infection
with MRSA was suspected or confirmed within the first
72 hrs of enrollment. The aminopenicillin/β-lactamase
inhibitor and vancomycin (by serum levels) could be
dose-adjusted per local guidelines. If culture results failed
to isolate MRSA, vancomycin could be discontinued.
Subjects
Subjects were eligible for the study if they were 18 yrs or
older and required hospitalization for cSSSI including deep
soft tissue infection (e.g., cellulitis ≥10 cm, requiring sur-
gery/drainage or with complicated underlying disease [e.g.,
diabetes mellitus, peripheral vascular disease, peripheral
neuropathy, or venous insufficiency]), major abscess,
infected ulcers, or burns <5% body surface area. The sub-
ject also had to have at least two of the following signs and
symptoms: fever, erythema, drainage/discharge, swelling/
induration, localized warmth, pain/tenderness, and white
blood cell count >10,000/mm3 or >10% immature bands.
Subjects were excluded if they had an uncompli-
cated skin infection (e.g., simple abscesses, folliculitis,
impetiginous lesions, furunculosis, or superficial cellulitis)
or an infection that could be treated by drainage or
wound care alone. Subjects with necrotizing infections,
osteomyelitis, likely amputation, retained devices, and
chronic infected (>1 week) ulcers were excluded. Sub-
jects with chronic diabetic foot infection (DFI) were
excluded. Subjects with hepatic disease or creatinine
clearance <30 mL/min were also excluded from the
study. Subjects could not receive more than 24 hrs of
prior antibiotic therapy, unless they were a failure on
prior antibiotic therapy (i.e., received prior antibiotics for
≥3 days with no improvement in the clinical signs and
symptoms of infection). Subjects who were prior anti-
biotic failures required a baseline culture prior to the first
dose of antibiotic in order to be eligible for the study. Sub-
jects with hypersensitivity to study medications or subjects
with concomitant infections that required treatment with
another antimicrobial agent were excluded. Subjects with
suspected or known Pseudomonas aeruginosa infections
were excluded unless P. aeruginosa was part of a polymi-
crobial infection and the subject was continuing to
improve.
Randomized subjects were included in the intent-to-
treat (ITT) population. Subjects who received at least
one dose of study drug were included in the modified
ITT (mITT) or safety population. Subjects meeting the
minimal disease criteria were included in the clinical
modified ITT (c-mITT) population. The clinically evalu-
able (CE) population comprised c-mITT subjects who
met all inclusion/exclusion criteria and had a clinical
response of either cure or failure at the test-of-cure
(TOC) assessment 8-50 days following the end of therapy
(EOT). Subjects with confirmed baseline isolates were
included in the microbiologic-modified ITT (m-mITT)
and microbiologically evaluable (ME) population, respect-
ively. ME subjects also had to have at least one isolate
susceptible to both test articles.
Efficacy and safety evaluations
A clinical response of cure, failure, or indeterminate was
determined by each investigator at the EOT and TOC
assessment. Subjects were cured if they had resolution
or improvement of symptoms such that no further anti-
biotic therapy was required. Subjects were considered
failures if they had an inadequate response requiring
additional antibiotic therapy or additional surgical ther-
apy to eradicate the infection. Subjects were considered
failures if they switched to oral therapy or were considered
indeterminate if clinical response could not be deter-
mined. Microbiologic efficacy (eradication/persistence)
was determined at the subject and isolate levels. Adverse
events (AEs) were collected from the time of informed
consent throughout the study period.
When clinically appropriate, specimens from the site
of infection were obtained at baseline and during the
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study. Blood cultures were obtained at baseline and there-
after when clinically indicated, and organism identification
and susceptibility testing were confirmed at a central
laboratory (Covance Clinical Laboratories, Indianapolis,
IN). Minimum inhibitory concentrations (MIC) were
determined by broth microdilution and by Kirby-Bauer
disk diffusion (tigecycline only) according to procedures
published by the Clinical and Laboratory Standards Insti-
tute (CLSI) [15,16]. CA-MRSA was defined in this study
as the presence of staphylococcal cassette chromosome
mec (SCCmec) type IV typing as determined by multi-
plex polymerase chain reaction.
Statistical analysis
Statistical analysis was performed by the Clinical Biostatis-
tics Department, Quintiles (Bloemfontein, South Africa).
The primary efficacy endpoint was the clinical response in
the CE population at the TOC. Assuming an evaluability
rate of at least 60%, approximately 500 subjects were
planned to be enrolled to obtain 300 CE subjects. As-
suming the two treatments to be equally effective, with
favorable clinical response rates (i.e., cure rates) of 80%
at the TOC visit, 150 subjects per treatment group were
required to ensure with 90% power that the lower bound
of a two-sided 95% confidence interval (CI) for the true dif-
ference in efficacy (tigecycline minus comparator) cor-
rected for continuity did not exceed -15%.
The noninferiority of tigecycline compared with com-
parator was evaluated for clinical and microbiological
response by using a two-sided 95% CI for the true
difference in efficacy (tigecycline minus comparator).
Noninferiority was concluded if the lower limit of the
two-sided CI was greater than -15%. Baseline variables,
AEs, and health outcome data were compared with
Fisher’s exact test, one-way analysis of variance with
treatment as a factor, or log-rank test as appropriate. For
subpopulation analyses, an adjusted difference between
treatment groups was used. Comparisons involving small
sample sizes were analyzed by the method of Wilson
[17], corrected for continuity. The “exact” method of
Clopper and Pearson [18] was used to determine the
two-sided 95% CI for a single proportion. Throughout
this article, significant refers to a p value <0.05.
Results
A total of 550 subjects were enrolled and randomized.
Nineteen subjects did not receive study drug and all sub-
jects met severity of infection criteria (Figure 1). Fifty-
nine tigecycline and 67 comparator subjects did not meet
evaluability criteria (p = 0.360). No clinical evaluation
at TOC, use of prohibited/concomitant medication,
inclusion/exclusion criteria not met, and insufficient
treatment duration were the most common reasons
for non-evaluability. Five subjects were excluded from
the ME population because of isolates not susceptible to
both test articles; in each case resistance was present for
the comparator drug.
Patients’ characteristics
Baseline characteristics including demographics, comor-
bid conditions, and clinical diagnoses were similar for
both treatment groups (Table 1). Thirty-two percent of
patients had diabetes mellitus. Cellulitis was the most
common diagnosis (63% of the total infections and 92%
of subjects with deep soft tissue infection). The most
common sites of infection were the lower extremity
(61.6%) and upper extremity (16.2%). Lesion size was
≥10 cm in length or width (where anatomically feasible)
for 74.9% of subjects. Spontaneous infection (60.3%),
trauma (20.7%), and previous surgery (7.5%) were the
most common causes of infection. Mean duration of
treatment in both treatment groups was 8 days. The
number of subjects who required any baseline procedure
(e.g., debridement, incision, and drainage) for the infec-
tion was similar (tigecycline 41.8% versus comparator
46.4%; p = 0.295). Thirty-eight percent of comparator
subjects received at least one dose of adjunctive vanco-
mycin therapy.
Clinical outcomes
Tigecycline met the predefined statistical criteria for non-
inferiority in the primary efficacy (CE) population. Tigecy-
cline cured 162/209 (77.5%) subjects and the comparator
cured 152/196 (77.6%) subjects (difference 0.0; 95% CI:
-8.7, 8.6). Similar results were seen in the other study
populations including the MITT population where 70.1%
of tigecycline-treated subjects and 68.8% of comparator-
treated subjects were cured (difference 1.3; 95% CI: -6.9,
9.5). Clinical responses in both treatment groups were
similar based on clinical diagnoses and comorbidities
(Table 2). Tigecycline efficacy in the CE population
(77.5%) was similar to comparator subjects who did
(72.7%) and did not (80.0%) receive vancomycin adjunct-
ive therapy. No differences in cure rates were observed
between treatment groups in either those who did or did
not require baseline procedures (data not shown).
Clinical cure rates for pathogens commonly found in
cSSSI were comparable between the two groups (Table 3).
Cure rates for subjects with methicillin-susceptible
S. aureus (MSSA) were higher than cure rates for sub-
jects with MRSA. In the ME population, clinical cure
rates for concomitant bacteremia with a skin pathogen
were 5/8 (62.5%) in tigecycline-treated subjects and
4/5 (80.0%) for comparator-treated subjects.
Microbiology and microbiologic response
Within the m-mITT population, S. aureus was isolated
in 58% of subjects with half (29%) demonstrating
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methicillin-resistance. Seventy-four percent of MRSA were
CA-MRSA with SCCmec type IV. S. aureus MIC90 value
for vancomycin was 1 μg/mL with 97% of isolates having an
MIC of ≥1 μg/mL. Tigecycline MIC90 values for S. aureus
and Streptococcus pyogenes were 0.25 μg/mL and 0.06 μg/
mL, respectively. Gram-negatives (excluding Pseudomonas
spp.), anaerobes, and polymicrobial infections were identi-
fied in 42%, 5%, and 43% of m-mITT subjects, respect-
ively. Polymicrobial infections involving at least one
Gram-positive and one Gram-negative pathogen occurred
in 19% of infections. During therapy, reduced susceptibility
to tigecycline was not identified in any isolate.
At the subject level, the eradication rates at the TOC as-
sessment for the ME population were 79.2% in the tigecy-
cline treatment group and 76.8% in the comparator
treatment group (difference 2.4%; 95% CI: -9.6, 14.4).
Within the ME population, the clinical response rate for
tigecycline-treated subjects with monomicrobial infections
was 86.4% compared with 72.4% for comparator-treated
subjects (difference 13.9; 95% CI: -1.8, 29.7). For
Figure 1 Analysis population. Footnote: *Subjects could be excluded for more than 1 reason. ITT, intent-to-treat; mITT, modified intent-to-treat;
TGC, tigecycline; Comp, comparator. c-mITT, clinical modified intent-to-treat; TOC, test-of-cure; m-mITT, microbiologic-modified intent-to-treat; CE,
clinically evaluable; ME, microbiologically evaluable.
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polymicrobial infections, the clinical response rate for
tigecycline-treated subjects was 72.2% compared with
85.4% for comparator-treated subjects (difference -13.1;
95% CI: -31.4, 5.1).
Health outcomes
Mean days of primary inpatient hospitalization did not
differ between the treatment groups (tigecycline 8.54
versus comparator 8.78; p = 0.650). The proportion of
subjects requiring readmission to the hospital was similar
between the tigecycline and comparator treatment group
(9.3% versus 8.0%; p = 0.645). Both groups were compar-
able in other post-hospital resource utilization such as
nursing home and home health services (data not
shown).
Safety/tolerability
Seventy percent of subjects reported at least one
treatment-emergent AE (TEAE). A total of 201/268
(75.0%) subjects who received tigecycline and 169/263
(64.3%) subjects who received comparator (p = 0.008)
reported TEAEs. Excluding nausea, vomiting, and diar-
rhea, there was no difference in the rate of TEAEs be-
tween the two treatment groups (p = 0.326). Table 4
shows the TEAEs that occurred in ≥3% of subjects. Nau-
sea and vomiting events were almost exclusively mild to
moderate in severity (NCI grades 1 and 2). No investigator
reported Clostridium difficile-associated diarrhea.
Overall, 16/268 (6.0%) tigecycline subjects and 8/263
(3.0%) comparator subjects discontinued study drug be-
cause of an AE (p = 0.143) with no significant differences
between treatment groups in the frequency of any single
AE leading to discontinuation of study drug. Nine






Age, years, mean (SD) 51.1 (16.11) 51.54 (16.90)







Weight, mean (SD) 87.8 (30.6) 90.4 (34.8)
Creatinine clearance, mL/min, mean (SD) 114.23 (60.73) 112.88 (59.94)
Comorbid conditions (%)
Diabetes mellitus 31.7 32.7
Peripheral vascular disease 14.2 11.0
IV drug use 4.5 4.6
Prior antibiotic failure (%) 20.5 22.4
Clinical diagnosis, n (%)*
Deep soft tissue infection† 186 (69.4) 176 (66.9)
Major abscesses 47 (17.5) 60 (22.8)
Infected ulcers 31 (11.6) 26 (9.9)
*Includes 3 burns and 1 “other” diagnosis in tigecycline subjects and 1 burn
in comparator subjects. †Includes cellulitis (168 and 166 patients in the
tigecycline and comparator groups, respectively), wound infections (8 and
6 patients, respectively), bites (8 and 4 patients, respectively), and IV catheter
infections (2 and 0 patients, respectively). ‡No statistically significant
differences between groups. mITT, modified intent-to-treat; SD, standard
deviation.




















Major abscess 30/36 (83.3) 34/43 (79.1) 4.3 (-15.5, 24.0)
Infected ulcers 17/22 (77.3) 15/20 (75.0) 2.3 (-28.3, 32.9)
Other populations
Diabetes mellitus 46/60 (76.7) 46/66 (69.7) 7.0 (-10.0, 24.0)
Peripheral vascular
disease
20/27 (74.1) 16/20 (80.0) -5.9 (-34.4,
22.5)
Prior antibiotic failure 27/35 (77.1) 26/34 (76.5) 0.7 (-22.1, 23.5)
*Includes 2 CE patients with burns: 1 tigecycline cure and 1 comparator
failure; †Calculated using asymptomatic method corrected for continuity. CE,
clinically evaluable; CI, confidence interval.
Table 3 Clinical cure rate at the isolate level: selected
baseline isolates at test-of-cure visit (ME population)*
Isolate Tigecycline Comparator
n/N % n/N %
Staphylococcus aureus 54/71 76.1 49/61 80.3
MRSA 25/36 69.4 21/29 72.4
CA-MRSA 17/25 68.0 17/23 73.9
MSSA 29/35 82.9 28/32 87.5
Streptococcus spp. 30/36 83.3 15/25 60.0
S. pyogenes 8/11 72.7 5/5 100
S. agalactiae 9/9 100 3/6 50.0
S. anginosus groupa 8/9 88.9 3/8 37.5
Enterobacter cloacae 5/8 62.5 1/1 100
Enterococcus spp.b 5/7 71.4 6/6 100
Escherichia coli 10/13 76.9 7/8 87.5
Klebsiella pneumoniae 5/5 100 5/6 83.2
Proteus spp.c 4/7 57.1 2/2 100
Pseudomonas aeruginosa 5/7 71.4 2/2 100
*No statistically significant differences between groups. ME, microbiologically
evaluable; MRSA, methicillin-resistant Staphylococcus aureus; CA-MRSA,
community-acquired MRSA; MSSA, methicillin-susceptible Staphylococcus
aureus. aStreptococcus anginosis, Streptococcus intermedius, Streptococcus
constellatus; bEnterococcus faecalis, Enterococcus faecium; cProteus mirabilis,
Proteus penneri, Proteus vulgaris group.
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tigecycline subjects and three comparator subjects dis-
continued study drug because of nausea and/or vomit-
ing. Serious AEs occurred in 14.2% and 11.0% of
tigecycline and comparator subjects, respectively (p =
0.297). Eleven subjects died during the study: six sub-
jects in the tigecycline treatment group and five subjects
in the comparator treatment group. The majority of
deaths were not attributed to the primary infection
under study; furthermore, four tigecycline deaths and
one comparator death occurred >30 days after the start
of therapy. All of these deaths were assessed by the
investigators as not related to study medication.
Discussion
Skin and skin structure infections frequently result in
hospitalization with significant morbidity and mortality.
Failure to initiate appropriate empiric medical therapy
can result in longer hospital stays, increased costs, and
mortality [19-21]. Recent increases in ambulatory visits
and hospitalization due to cSSSI have been attributed to
the increase of CA-MRSA [22,23]. In this study, the
most common pathogen was S. aureus, which was iso-
lated in more than half of all subjects in the m-mITT
population. Half of the S. aureus isolates demonstrated
methicillin resistance, and 74% of them were CA-MRSA.
The majority of all S. aureus isolates had vancomycin
MICs of ≥1 μg/mL consistent with prior observations of
vancomycin MIC creep [24,25]. However, a more diverse
microbiological spectrum of pathogens in skin infections
has previously been reported and was observed in this
study [2,3]. Therefore, empiric treatment of hospitalized
subjects with cSSSI may require broad spectrum anti-
biotic regimens and may require activity against MRSA.
A working group in South Africa has published guide-
lines on the appropriate use of tigecycline and has pro-
vided clinical scenarios that may be useful to clinicians
[26]. In particular they have suggested that directed ther-
apy against polymicrobial infections that include resistant
pathogens such as extended spectrum β-lactamases and
empiric therapy for subjects at risk of such infections
would be supported. Patients with prior antibiotic expos-
ure or failure, renal insufficiency, or β-lactam allergy may
also benefit from tigecycline.
In this study, tigecycline was effective as empiric
monotherapy in the treatment of hospitalized subjects
with cSSSI. Tigecycline monotherapy was non-inferior
to a commonly prescribed antibiotic for cSSSI, the
aminopenicillin/β-lactamase inhibitor (±vancomycin).
These results confirmed and are consistent with the
results of two previous randomized, double-blind, active-
controlled, multinational, multicenter phase 3 trials
[13,14]. The combined clinical cure rate in the previous
two studies was 86.5% in the tigecycline group versus
88.6% in the vancomycin/aztreonam group, (difference
-2.1%; 95% CI: -6.8 to 2.7) [27].
Both tigecycline and comparator were generally well
tolerated. Tigecycline has increased gastrointestinal AEs
consistent with other tetracycline antibiotics; however,
the severity of the nausea and vomiting were almost ex-
clusively mild to moderate and few subjects required
treatment discontinuation. An increase in all-cause mor-
tality has been observed in the tigecycline clinical pro-
gram; however, a difference was not observed in this
study or in the cSSSI indication (risk difference 0.7; 95%
CI: -0.5, 1.9) [28]. Overall, tigecycline was demonstrated
to be safe in this clinical trial and the safety profile is
consistent with prior cSSSI trials.
Two strengths of this study were that more than 60%
of subjects presented with cellulitis and 20% were prior
antibiotic failures. In a recent paper on the justification
for noninferiority margins in cSSSI trials, the greatest
benefit for antimicrobial therapy was seen in patients
with cellulitis and erysipelas [29]. In a recent health out-
comes paper, Edelsberg and colleagues demonstrated
worse outcomes and increased resource utilization in
cSSSI patients who were prior antibiotic failures [19]. In
the current study, tigecycline compared favorably with
the comparator regimen in subjects who had cellulitis and
in subjects who were prior antibiotic failures (Table 2).
The major limitation of this study is its open-label design
and the potential bias on the outcomes. However, the
Table 4 Treatment-emergent adverse events in ≥3% of
mITT subjects
Adverse Event Tigecycline Comparator
N = 268 N = 263
n (%) n (%)
Nausea* 117 (43.7) 44 (16.7)
Vomiting* 64 (23.9) 14 (5.3)
Diarrhea* 39 (14.6) 14 (5.3)
Constipation 17 (6.3) 22 (8.4)
Dyspepsia 17 (6.3) 7 (2.7)
Headache 20 (7.5) 22 (8.4)
Pain† 15 (5.6) 18 (6.8)
Abdominal pain 17 (6.3) 7 (2.7)
Fever 9 (3.4) 6 (2.3)
Chest pain 6 (2.2) 8 (3.0)
Insomnia 22 (8.2) 17 (6.5)
Anxiety 9 (3.4) 7 (2.7)
Dizziness 9 (3.4) 6 (2.3)
Hypokalemia* 6 (2.2) 17 (6.5)
Pruritis 15 (5.6) 16 (6.1)
Hypertension 8 (3.0) 9 (3.4)
Anemia 8 (3.0) 7 (2.7)
*Significant between-group difference (p < 0.05). †Pain was a general category
for any pain without a more specific category (e.g., abdominal pain). mITT,
modified intent-to-treat.
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outcomes are consistent with prior double-blinded stud-
ies in cSSSI.
This trial and the two previous clinical trials in
cSSSI support the efficacy and safety of tigecycline
use in this patient population [13,14]. Tigecycline has
been included in the Surgical Infections Society’s
updated guidelines for the management of cSSIs, spe-
cifically for the treatment of rapidly progressive soft tis-
sue infections due to S. aureus and MRSA [20]. The
Infectious Disease Society of America’s (IDSA) guide-
lines on the treatment of MRSA acknowledged the
approved use of tigecycline within this indication but
did not include tigecycline in its recommendations be-
cause of available MRSA-active alternatives and the in-
crease in all-cause mortality noted in the tigecycline
clinical program [30]. Recently, the IDSA guidelines on
DFIs [31] has listed tigecycline as a suggested empiric
regimen despite tigecycline not meeting primary study
endpoints in its DFI clinical trial.
Conclusions
In conclusion, tigecycline was non-inferior to ampicillin-
sulbactam or amoxicillin-clavulanate with or without
vancomycin in the treatment of cSSSI. This trial and the
two previous clinical trials in cSSSI support the efficacy
and safety of tigecycline use in this patient population.
Given its broad spectrum in vitro activity, tissue penetra-
tion, and clinical trial results, tigecycline continues to
offer an effective and safe alternative option, where ap-
propriate, in the empiric treatment of hospitalized
patients with cSSSI.
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